Elixir Associates reposted this
Headhunting Talented Individuals within Clinical Operations & Clinical Development for growing organizations across the US & Europe
AstraZeneca has just unveiled a game-changing biomarker for the NSCLC landscape, thanks to a partnership with Daiichi Sankyo for their drug, datopotamab deruxtecan (Dato-DXd). Developed using AI, this new biomarker, called the Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring (NMR-QCS), could be a critical differentiator in tackling non-small cell lung cancer. **Key Highlights:** ✔️ **Innovative Approach:** Unlike traditional biomarkers, the NMR-QCS examines the ratio of TROP2 expression between the cell membrane and cytoplasm. ✔️ **Clinical Impact:** In a recent study presented at the World Conference on Lung Cancer, patients with NMR-QCS-positive tumors taking Dato-DXd saw a 43% lower risk of tumor progression or death compared to those on chemotherapy. ✔️**Collaborative Efforts:** AstraZeneca is partnering with Roche to develop a companion diagnostic to ensure the biomarker's widespread application, potentially revolutionizing treatment strategies for NSCLC patients. AstraZeneca is also collaborating with Roche to develop a companion diagnostic to ensure the biomarker's widespread application. This could provide invaluable insights and targeted treatment options for both patients and healthcare providers. #Innovation #LungCancer #AI #Healthcare #ClinicalResearch #AstraZeneca #DaiichiSankyo #Roche #LifeScience #ElixirAssociates #StaffingPartner
